ArcherDX, Inc., a leader in NGS fusion detection, in partnership with Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, today launched the Archer™ SureShot™ ALK, RET, ROS1 Fusion Control to benchmark greater confidence in gene fusion detection using Archer FusionPlex™ Panels. The reference control is comprised of FFPE curls of homogenously mixed, precisely defined cell lines that contain EML4-ALK, CCDC6-RET and SLC34A2-ROS1 fusions.

“When used alongside FusionPlex Panels that contain ALK, RET or ROS1 fusions, the SureShot controls are a powerful measure of extraction, library preparation, sequencing and panel performance,” says Brian Kudlow, PhD, Director of NGS Applications and Chemistry at ArcherDX.

Dr Paul Morrill, President, Products, Horizon Discovery Group, said: “We are pleased to see the launch of this new reference control developed in partnership with ArcherDX. Horizon’s ongoing relationship with...

Jason Myers, PhD, CEO at ArcherDX, said “The fusion targets present in SureShot are particularly important driver mutations in lung cancer. However, the low incidence rates of these mutations make it difficult for laboratories to obtain consistent sources of controls. Through our partnership with Horizon, we now provide a consistent and accurate FFPE control to our customers.”

SureShot Negative Controls are also available, containing 100% wild-type cells that carry no target-gene fusion.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?